Organic Active Ingredients TRIZ Cases

Palladium-catalyzed thienopyrimidine synthesis achieves selective Class Ia PI3K inhibition, resolving broad kinase activity trade-offs.

Inhibiting biliverdin IXβ reductase increases platelet counts while avoiding thromboembolic complications linked to TPO axis targeting.

Substituted pyridopyrimidines target specific PI3K isoforms to overcome the poor selectivity of first-generation kinase inhibitors.

A metallo-lactoferrin and coenzyme composition triggers intracellular adenosine triphosphate release through proton gradient recreation.

Antisense oligonucleotides block exon junction complex deposition to stabilize mRNA transcripts.

Crystalline salt forms of a pyrimidine derivative enhance bioavailability, resolving formulation complexity while improving therapeutic efficacy.

Fused pyrroledicarboxamides inhibit TASK-1 channels to treat arrhythmias while avoiding hERG-mediated cardiotoxicity.

An osmotic pump system delivers nifedipine over 24 hours while an outer coating releases angiotensin-II antagonists rapidly to stabilize plasma levels.

Nanoparticles coated with cationic polymers and stabilizers deliver antigens to stimulate immune responses.

Sulfonamide derivatives with fused pyrimidine skeletons suppress cancer cell growth driven by EGFR mutations while minimizing side effects on normal cells.

FLT3 receptor antagonists block nociceptor sensitivity to alleviate neuropathic pain symptoms.

A coacervate system delivers cytokines via localized sustained release.

Phytate adsorbs onto calcium phosphate crystals to stabilize bone mineral, addressing the bottleneck of existing crystal dissolution in osteoporosis treatment.

Targeted pharmacological regimens prevent transplanted xenogeneic organs from overgrowing within recipient primates, ensuring stable long-term function.

Creatine kinase derived peptides isolate analgesic activity from harmful side effects to reverse neuropathic pain.

Novel compounds bind wild-type and mutant PKR to induce tetramer formation, treating pyruvate kinase deficiency without invasive surgery.

5α-androstane-3β,5,6β-triol reduces vasogenic edema and neuronal degeneration caused by hypobaric hypoxia.

Ginseng berry extract stimulates nitric oxide generation to improve blood circulation and enhance endothelial cell viability.

Co-administering a c-Met/EGFR dual inhibitor with an IGF-1R inhibitor to simultaneously target multiple oncogenic pathways.

Small extracellular vesicles deliver specific microRNAs to regulate PTX3 expression levels in therapeutic agents.

Oxygen scavengers and pH adjustment prevent oxidation and deacetylation, maintaining injectable paracetamol stability in plastic containers.

Mechanical extrusion detaches stromal precursor cells from collagen matrices, eliminating enzymatic treatments that increase clinical trial duration.

Chitosan nanoparticles encapsulate anti-galectin-1 siRNA for intranasal delivery across the blood-brain barrier.

Macroporous resin adsorption isolates high-acetyl monomeric polysaccharide ME-2, preserving structural integrity while removing proteins and pigments.

Lipid nanoparticle formulations protect nucleic acids from enzymatic degradation while achieving high transfection efficiency and targeted release.

Smad3 inhibitors target the TGF-beta pathway to reduce severe side effects while effectively suppressing tumor growth and invasion.

Benzylamino substituted pyridopyrimidinones bind the SOS1 catalytic site to block RAS-family protein interactions.

Segmenting the molecule into functional modules resolves targeting difficulty while maintaining therapeutic effectiveness for lung and colon cancers.

AICAr triggers LRRK2 mRNA decay to lower toxic protein levels, addressing delayed onset and side effects of current therapies.

Tetraaza-cyclopentaindenyl compounds act as positive allosteric modulators at the muscarinic M1 receptor.

Pharmaceutical compositions inhibit CD44-Moesin binding via small molecules, reducing neuroinflammation and protecting neurons from necroptosis.

Parthenolide analogues target NF-kB signaling pathways to eliminate chemotherapy-resistant cancer stem cells and reverse tumor recurrence.

Coaxial counter-rotating rotors compensate for torque to enable vertical flight, reducing mechanical complexity compared to conventional helicopters.

Asymmetric needle tip deflects off choroid tissue to prevent trauma while delivering thixotropic drug formulations into suprachoroidal space.

Novel oxazepine compounds selectively inhibit late sodium currents to treat cardiovascular diseases and diabetes.

A cationic polymeric matrix forms stable complexes with negatively charged macromolecules to enhance mucosal absorption.

A pharmaceutical composition combining cilostazol and edaravone treats cerebrovascular diseases through synergistic therapeutic mechanisms.

Ibuprofen hybrid conjugates link the drug to amino acids or 4-aminophenol, reducing ulcerogenic effects while maintaining anti-inflammatory efficacy.

A Cholix-derived carrier binds therapeutic proteins to internalize them via receptor-mediated endocytosis.

Specific heteroaryl compounds constrain Bcl-xL proteins to trigger apoptosis in cancer cells while sparing normal cell toxicity.

Biodegradable particles deliver cytokine-antibody fusion proteins to selectively expand antigen-specific regulatory T cells, avoiding broad immunosuppression.

Segmented transdermal patches maintain steady serum levels to eliminate withdrawal bleeding and adverse events from oral dosing interruptions.

Polysubstituted imidazopyridine compounds enhance therapeutic efficacy and specificity by targeting Nurr-1 nuclear receptors for disease treatment.

A wet granulation process using dibasic calcium phosphate and microcrystalline cellulose creates stable levetiracetam tablets.

A 1H-NMR method using dimethylmalonic acid as an internal standard quantifies glycosaminoglycan signals for accurate monosaccharide composition analysis.